ASH Clinical News ACN_5.2_digital | Page 23

ONLY
ONLY
NCCN
CATEGORY 1
Lenalidomide (REVLIMID) +
low-dose dex: the ONLY preferred
NCCN Category 1 doublet for
NSCT NDMM patients 1
FDA
APPROVED
MAINTENANCE
THERAPY
The ONLY FDA-approved
maintenance therapy
post auto-HSCT 2
1
#
PRESCRIBED
The most prescribed
NDMM therapy 3 †
Lenalidomide (REVLIMID):
the ONLY preferred NCCN
Category 1 maintenance therapy
post auto-HSCT 1 *
Choose REVLIMID as a standard of care
for NSCT and post auto-HSCT patients 2
NCCN, National Comprehensive Cancer Network ® ;
NDMM, newly diagnosed multiple myeloma; NSCT,
non-stem cell transplant.
* NCCN makes no warranties of any kind whatsoever
regarding their content, use, or application and disclaims
any responsibility for their application or use in any way.
† Claims data 04/2015-03/2018. Source: IntrinsiQ Data.
© 2018, IntrinsiQ Specialty Solutions, Inc.